Abstract:Previous studies suggest that radiotherapy (RT) can induce immune activation, which not only reduces the progression of tumors, but also causes the release of tumor antigens. The combination of RT and immune checkpoint blockade, such as the inhibition of programmed cell death 1 (PD‑1) and programmed cell death ligand 1 (PD‑L1), has been demonstrated to yield impressive response rates. However, a substantial proportion of patients develop resistance such therapies. Previous studies have shown that indoleamine 2,3‑dioxygenase (IDO) causes T cell exhaustion and increased formation of regulatory T cells (Tregs), upregulating the expression of inhibitory receptors and ligands. Therefore, the application of IDO inhibitors combined with RT may have a synergistic effect by relieving immunosuppression. Lewis lung cancer cell‑bearing mice were treated with the IDO inhibitor 1‑methyl‑tryptophan (1MT) and/or 10 Gy RT. Tumor size was measured every day, flow cytometry was performed to measure the expression of dendritic cell (DC) maturation markers, inhibitory receptors, ligands, cytotoxic T cells and Treg phenotypic markers. Reverse transcription‑quantitative PCR was used to evaluate the mRNA expression levels of IDO, PD‑L1, PD‑1, T cell immunoglobulin domain and mucin domain 3 (TIM‑3), B‑ and T‑lymphocyte attenuator (BTLA) and galectin‑9. Compared with the control group, treatment with 1MT or RT reduced tumor growth, however, the combination therapy was more effective than either treatment alone. Flow cytometry showed the upregulation of CD80, CD86 and the major histocompatibility complex II in spleen DCs and the concurrent downregulation of CD4, CD25 and forkhead box protein P3 in lymphocytes in the treatment groups. Compared with the control group, inhibitory receptors and ligands that affect DCs and T cells were observed, expression levels of PD‑L1, PD‑1, TIM‑3, BTLA and galectin‑9 are decreased in treatment group compared with control. IDO inhibition synergized with RT to downregulate Tregs, inhibitory receptors and ligands to prevent T cell exhaustion. By activating DCs and T cells, this combination therapy may strongly enhance antitumor immunity and inhibit tumor progression.

Ganoderic Acid Me Induces the Apoptosis of Competent T Cells and Increases the Proportion of Treg Cells Through Enhancing the Expression and Activation of Indoleamine 2,3-Dioxygenase in Mouse Lewis Lung Cancer Cells.

Enhancement of Il-2 and Ifn-Gamma Expression and Nk Cells Activity Involved in the Anti-Tumor Effect of Ganoderic Acid Me in Vivo

Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment

Ganoderic Acid DM Induces Autophagic Apoptosis in Non-Small Cell Lung Cancer Cells by Inhibiting the PI3K/Akt/mTOR Activity.

Ganoderic acid T from Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung cancer cells.

Gambogic Acid Induced Tumor Cell Apoptosis by T Lymphocyte Activation in H-22 Transplanted Mice

Immunoactivative Role of Indoleamine 2,3‑dioxygenase in Gastric Cancer Cells in Vitro.

[Knockdown of Indoleamine 2, 3-Dioxygenase 2 (ido2)gene Inhibits Tumor Growth and Enhances Immune Function in Mice Bearing Melanoma].

Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma

Ganoderic Acid Me Induces Apoptosis Through Mitochondria Dysfunctions in Human Colon Carcinoma Cells

Tumor Immune Escape of a Gastric Cancer Cell Line Expressing Indoleamine 2,3-Dioxygenase(ido)

Indoleamine 2,3-dioxygenase-1 involves in CD8 + T cell exhaustion in glioblastoma via regulating tryptophan levels

Activated Cd69(+) T Cells Foster Immune Privilege by Regulating Ido Expression in Tumor-Associated Macrophages

IDO1 Inhibition Promotes Activation of Tumor-intrinsic STAT3 Pathway and Induces Adverse Tumor-protective Effects

GBP1 Facilitates Indoleamine 2,3-Dioxygenase Extracellular Secretion to Promote the Malignant Progression of Lung Cancer

Gene silencing of indoleamine 2,3-dioxygenase 2 in melanoma cells induces apoptosis through the suppression of NAD+ and inhibits in vivo tumor growth.

Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non-Small Cell Lung Cancer

IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion

The impact of IDO2 expression in B16-BL6 cells on melanoma formation and growth

Inhibition of Indoleamine 2,3-Dioxygenase Enhances the Therapeutic Efficacy of Immunogenic Chemotherapeutics in Breast Cancer.

Tobacco Carcinogen Induces Tryptophan Metabolism and Immune Suppression Via Induction of Indoleamine 2,3-Dioxygenase 1